ADBICA
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChemCID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard(EPA) |
|
Chemical and physical data | |
Formula | C20H29N3O2 |
Molar mass | 343.471g·mol−1 |
3D model (JSmol) |
|
| |
|
ADBICA(also known asADB-PICA) is adesigner drugidentified insynthetic cannabisblends in Japan in 2013.[1]ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, likeSDB-001andSTS-135.The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.[2]ADBICA is a potentagonistof theCB1receptorandCB2receptorwith an EC50value of 0.69 nM and 1.8 nM respectively.[3]
Legal Status
[edit]As of October 2015 ADBICA is a controlled substance in China.[4]
See also
[edit]References
[edit]- ^Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products".Forensic Toxicology.31(2): 223–240.doi:10.1007/s11419-013-0182-9.S2CID1279637.
- ^WO 2009/106980,Buchler IP, et al, "Indazole Derivatives", assigned to Pfizer, Inc.
- ^Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA".ACS Chemical Neuroscience.6(9): 1546–59.doi:10.1021/acschemneuro.5b00112.PMID26134475.
- ^"Về in và phát hành 《 phi dược dùng loại gây tê dược phẩm cùng tinh thần dược phẩm liệt quản biện pháp 》 thông tri"(in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe originalon 1 October 2015.Retrieved1 October2015.